The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Risk stratification in MDS
Hege Garelius
• 9 Jun 2022
Hege Garelius, MD, Sahlgrenska University Hospital, Göteborg, Sweden, comments on risk stratification in myelodysplastic syndromes (MDS), highlighting the importance of incorporating mutations in these classifications. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
